ArticleFrontiers in medicine2026
Renal function and urinary tubular biomarker abnormalities in untreated and entecavir- or tenofovir disoproxil fumarate-treated patients with chronic hepatitis B: a retrospective cross-sectional study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal safety is an important consideration during nucleos(t)ide analogue (NA) therapy for chronic hepatitis B (CHB). Tenofovir disoproxil fumarate (TDF) may affect proximal tubular function, while serum creatinine and estimated glomerular filtration rate (eGFR) primarily reflect glomerular filtration. This study compared glomerular-function measures and urinary tubular biomarker patterns among NA-untreated, entecavir (ETV)-treated, and TDF-treated patients with CHB. Methods: This single-center retrospective cross-sectional study included 242 adults with CHB assessed between June 2025 and June 2026: 113 NA-untreated, 64 ETV-treated, and 65 TDF-treated participants. For treated participants, the single index assessment was obtained after at least 12 months of continuous corresponding monotherapy. Serum creatinine, eGFR, urinary Results: Urinary A1M ≥ 12.0 mg/L occurred in 13.3%, 42.2%, and 67.7% of NA-untreated, ETV-treated, and TDF-treated participants, respectively; corresponding frequencies of urinary B2M > 0.30 mg/L were 25.7%, 48.4%, and 75.4%. Both A1M and B2M concentration-threshold exceedance were more frequent in TDF-treated than ETV-treated participants (Bonferroni-adjusted Conclusion: TDF-treated participants showed a more prominent urinary A1M/B2M concentration-based biomarker pattern than ETV-treated participants, whereas conventional glomerular-function measures did not differ between the two treated groups. These findings represent cross-sectional associations rather than evidence of treatment-induced renal injury. The absence of pretreatment and serial renal measurements, urinary creatinine normalization, and a complete proximal tubular dysfunction assessment requires cautious interpretation and prospective longitudinal confirmation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.